(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/049613 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
C07K 16/46 (2006.01) *A61K 39/00* (2006.01)
A61P 35/02 (2006.01)

(21) International Application Number:
PCT/US2024/044238

(22) International Filing Date:
28 August 2024 (28.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/579,267 28 August 2023 (28.08.2023) US

(71) Applicants: **XENCOR, INC.** [US/US]; 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **JANSSEN BIOTECH, INC.** [—/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US).

(72) Inventors; and

(71) Applicants: **VLOEMANS, Nele**; c/o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044 (US). **CORNELISSEN, Ivo**; c/o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044 (US).

(72) Inventors: **MOORE, Gregory, L.**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **HEDVAT, Michael**; c/o Xencor, Inc., 111 West Lemon Avenue, Monrovia, CA 91016 (US). **DRAGOVICH, Matthew, Adam**; c/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). **FONTAN GABAS, Lorena**; c/o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044 (US). **ZWOLAK, Adam**; c/o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044 (US). **PHILIPPAR, Ulrike**; c/o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044 (US). **SETH, Pankaj**; c/o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Horsham, PA 19044 (US).

(74) Agent: **NGUYEN, Louis-Vu, T.** et al.; Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: ANTI-CD20 X ANTI-CD28 COMBINATION THERAPIES

(57) Abstract: Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.

Figure 31A





Figure 31B



WO 2025/049613 A1

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*